Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Line Development Market

Cell Line Development Market Trends

Report ID: GMI429
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Cell Line Development Market Trends

Advanced techniques such as CRISPR/Cas9 and other genome editing tools allow precise modifications to cell lines, leading to higher expression of desired proteins and improved productivity.

For instance, in January 2023, Abzena announced the launch of AbZelect and AbZelectPRO, its new cell line development (CLD) platforms, designed to speed up the generation of production cell lines for the manufacture of antibodies and recombinant proteins. Thus, the introduction of technologically advanced cell line development tools such as reagents & media, and equipment is anticipated to propel the growth of market.

Moreover, innovations in cell line characterization and monitoring improve the quality and consistency of the cell lines, leading to more reliable and reproducible results in biomanufacturing that are further observed to drive the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The cell line development market was valued at USD 5.8 billion in 2023 and will grow at 10.3% CAGR during 2024-2032, driven by the global prevalence of cancer owing to adoption of sedentary lifestyles.

The reagents & media segment of the market recorded USD 2.6 billion in 2023 and will grow through 2032, driven by recurring demand for media and reagents during the cell line development process.

North America cell line development market secured 34.3% share in 2023 and will expand rapidly through 2032, driven by huge patient base prone to infectious and chronic diseases.

Advanced Instruments, LLC, Aragen Life Sciences Ltd., ASIMOV, Cytiva (Danaher Corporation), Eurofins Scientific, Fyonibio, GensSript Biotech, and Lonza Group AG among others.